Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Exclusion Criteria

• •1. Active brain metastases or leptomeningeal metastases
• •2. Diverticulitis or Symptomatic ulcerative disease
• •3. Treatment required complication of systemic infectious disease
• •4. Medical history of active, known, or suspected autoimmune disease
• •5. Complication of pulmonary fibrosis or interstitial pneumonitis
• •6. Medical history of clinically significant cardiovascular disease within 180 days of initial dose as New York Heart Association (NYHA) class above 2 leveled congestive heart failure, unstable angina, cardiac infarction or cardiac arrhythmia with paroxysmal or required treatment
• •7. Regardless of usage of antihypertensive drug, systolic blood pressure \<=140 mm Hg and diastolic blood pressure \<=90 mm Hg
• •8. Have active double cancer
• •9. Currently receiving other interventional clinical study treatment